Table 3 Effect of intervention and control groups for HD on symptoms of depression and QoL at post-treatment and follow-up
Study ID | Time-point | Depression | QoL | ||||||
|---|---|---|---|---|---|---|---|---|---|
Measure | Intervention | Control | MD/SMD (95% CI) | Measure | Intervention | Control | MD/SMD (95% CI) | ||
Duarte (2009) [31] | post-treatment | BDI | 14.1 (8.7) | 21.2 (9.1) | MD: -7.1 (-10.88, -3.32) | KDQOL | Only sub-dimensions scores of the scale were reported | ||
follow-up (6 mon) | Â | 10.8 (8.8) | 17.6 (11.2) | MD: -6.8 (-11.07, -2.53) | |||||
Cukor (2014) [32] | post-treatment | BDI-II | 11.7 (9.8) | 14.5 (8.5) | MD: -2.8 (-7.47,1.87) | KDQOL | 115.3 (25.5) | 110.6 (25.1) | SMD: 0.18(-0.33,0.70) |
follow-up (3 mon) | Â | 9.9 (8.5) | 9.1 (6.5) | MD:0.8 (-3.03,4.63) | 118.3 (27.7) | 119.7 (24.7) | SMD: -0.05(-0.57,0.46) | ||
post-treatment | HAM-D | 6.5 (6.8) | 10.9 (5.4) | MD: -4.4 (-7.51, -1.29) | - | - | - | - | |
follow-up (3 mon) | Â | 6.7 (5.8) | 5.0 (4.3) | MD:1.7 (-0.87,4.27) | - | - | - | - | |
Lerma (2017) [30] | post-treatment | BDI | 10.2 (8.2) | 15.0 (10.9) | MD: -4.8 (-10.6,1.00) | CIQOLP | 109.6 (21.1) | 94.0 (21.0) | SMD: 0.73 (0.13,1.33) |
follow-up (1 mon) | Â | 7.1 (7.2) | 14.7 (9.7) | MD: -7.6 (-12.7, -2.45) | 112.5 (23.8) | 91.3 (22.5) | SMD: 0.89 (0.28,1.50) | ||
Valsara (2016) [33] | post-treatment | HADS | 6.82 (1.86) | 9.21 (2.69) | MD: -2.39 (-3.49, -1.29) | Not reported | |||
follow-up (3 mon) | Â | 6.73 (1.53) | 9.74 (2.71) | MD: -3.01 (-4.06, -1.96) | |||||
Mehrotra (2019) [34] | post-treatment | QIDS-C | 8.1 (5.1) | 5.9 (4.5) | MD:2.2 (0.43,3.97) | GQOL | 5.6 (5.0 to 6.2) | 6.4 (5.8 to 7.0) | - |
Al saraireh (2018) [35] | post-treatment | HADS | 15.0 (5.5) | 11.1 (2.3) | MD:3.9 (2.27,5.52) | Not reported | |||